Clinical InvestigationCancer Therapy-Induced Left Ventricular Dysfunction: Interventions and Prognosis
Section snippets
Methods
After Institutional Review Board approval, a comprehensive review was performed of all consecutive patients referred to the Stanford Cardiology clinic for treatment of cancer therapy-associated cardiac disease from August 2004 to July 2012. The primary inclusion criterion was referral to the cardiology clinic for the presence of any decline in LVEF to below normal, temporally associated with cancer therapy. In our laboratory, LVEF <55% is considered to be abnormal. Although we included all of
Results
Of 247 consecutive patients screened, 79 patients met the inclusion criteria. Baseline characteristics are included in Table 1. Although 10 malignancies were represented, the majority of the patients had either breast cancer (46%) or hematologic malignancies (35%). Most patients did not have significant cardiac comorbidities or preexisting use of cardiac medications.
The group underwent both medical (medications) and device (cardiac resynchronization therapy for left bundle branch block [LBBB])
Discussion
Advances in cancer therapeutics have led to the development of more effective chemotherapy agents, providing treatment options for even many aggressive cancers. Little literature exists to guide clinicians on the natural history of LVEF recovery following cancer therapies, particularly with newer targeted cancer therapies and with the use of cardiac medications. Among a cohort of patients who experienced a decline in LVEF, we aimed to describe how many were able to recover their cardiac
Disclosures
None.
References (21)
- et al.
The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients
J Am Coll Cardiol Heart Fail
(2013) - et al.
Risk factors for doxorubicin-induced congestive heart failure
Am J Med
(1977) - et al.
Reversibility of left ventricular dysfunction resulting from chemotherapy: can this be expected?
Prog Cardiovasc Dis
(2010) - et al.
Left ventricular dysfunction predicted by early troponin i release after high-dose chemotherapy
J Am Coll Cardiol
(2000) - et al.
Myocardial injury revealed by plasma troponin i in breast cancer treated with high-dose chemotherapy
Ann Oncol
(2002) - et al.
Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients
Ann Oncol
(2002) - et al.
Protective effects of carvedilol against anthracycline-induced cardiomyopathy
J Am Coll Cardiol
(2006) - et al.
Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies
J Am Coll Cardiol
(2013) - et al.
Beta-blockade in adriamycin-induced cardiomyopathy
J Card Fail
(2000) - et al.
Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines
J Lab Clin Med
(2005)
Cited by (47)
Cellular and Molecular Mechanisms of MEK1 Inhibitor–Induced Cardiotoxicity
2022, JACC: CardioOncologyCitation Excerpt :Following withdrawal of trametinib, hCO function and morphology began to trend toward baseline. These data suggest trametinib-induced cardiotoxicity may be reversible, consistent with clinical reports suggesting most patients achieve recovery in left ventricular function.34 Studies examining the use of drug holidays (brief treatment breaks) and the incidence of adverse events, as well as the impact on treatment efficacy, are warranted.
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations
2020, Annals of OncologyCitation Excerpt :Given the known cardiotoxic effects of TKI/anti-VEGF therapies, any new symptoms of HF should be investigated with at least an LVEF assessment and measurement of selected cardiac biomarkers. Because of the concern for asymptomatic-reduced LVEF and the potential to aggravate this finding, resulting in symptomatic HF, it is suggested that a cardiologist (preferably a cardio-oncology specialist) participate in the care of these patients.146,149 A thorough evaluation should be done and coordination of medication choices needs to be clarified with the treating oncologist.80,139
Chemotherapy Agents With Known Cardiovascular Side Effects and Their Anesthetic Implications
2017, Journal of Cardiothoracic and Vascular AnesthesiaIncidence and risk of cardiotoxicity in cancer patients treated with targeted therapies
2017, Cancer Treatment ReviewsCitation Excerpt :Egger’s test was f studies not significant or high-grade (z = 1.69, p = 0.09), thus suggesting a minor influence of bias sources in the identification of high-grade cardiotoxicy. Cardiotoxicity represents a fundamental issue in oncology clinical practice, since it correlates with poor outcome in cancer patients [69,70]. For this reason, it is crucial for both clinicians and patients to be aware about the risk of drug-induced cardiotoxicity in order to promptly take the appropriate measures to face these events.
LVEF by Multigated Acquisition Scan Compared to Other Imaging Modalities in Cardio-Oncology: a Systematic Review
2022, Current Heart Failure Reports
See page 158 for disclosure information.